Cyrus S. Poonawalla

Learn More
In 1978, 22 staff members of the National Institute of Virology, Pune, India, were given two doses of human diploid cell antirabies vaccine (HDCV) for primary pre-exposure prophylactic immunization; the interval between the two doses being approximately 4 weeks. Eighteen of these 22 vaccinees were given a booster dose 1 year later. All 18 vaccinees(More)
Over the last 4 years, a remarkable public health success has unfolded in Africa. The field introduction of a new group A meningococcal conjugate vaccine, PsA-TT (MenAfriVac), has been a stunning success, with the virtual disappearance of group A meningococcal meningitis in sub-Saharan Africa. The effort began with a plea from African ministers of health to(More)
BACKGROUND In 2002, the Meningitis Vaccine Project (MVP) chose the Serum Institute of India, Ltd (SIIL), as its manufacturing partner to establish a product development partnership (PDP) with the Meningitis Vaccine Project (MVP). MVP was a collaboration between PATH and the World Health Organization (WHO) to develop meningococcal conjugate vaccines for(More)
  • 1